The valve which is present in the right ventricle of human heart regulates the one-directional flow of blood from the right ventricle to the pulmonary artery. This valve is called the pulmonary valve. The under-developed or malfunctioning pulmonary valve observed within eight weeks of pregnancy leading to defective distribution of the blood throughout the body causes congestion in the heart which is observed in pulmonary atresia. Its symptoms being blue or grey-toned skin, troubled breathing, weakness, and sleepiness helps doctors diagnose the disorder. Prenatal ultrasound also aids in diagnosis of the problem. Change in lifestyle, rise in the number of parents with the recessive disorder, and environmental factors are some of the causes contributing to the increase in population suffering from pulmonary atresia. Pulmonary atresia requires detailed diagnosis and treatment. Hence, the factors causing the disorder are expected to be the driving factors for the pulmonary atresia diagnostics and treatment market to grow. Awareness of medical advancement is likely to be another factor pushing the global pulmonary atresia diagnostics and treatment market.
Get Free Sample Copy @https://www.marketresearchfuture.com/sample_request/6487
However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively.
Market Research Future (MRFR) in its report discuss the possible market constraints. Expensive surgical procedures and ambiguous reimbursement policies can obstruct the market expansion. MRFR asserts, the global pulmonary atresia diagnostics and treatment market is anticipated to grow with a substantial CAGR during the forecast period.
Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.
The segmental analysis of the global pulmonary atresia diagnostics and treatment market is based on type, diagnosis, treatment and end users.
Based on type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.
Based on diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.
Based on treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization segment is narrowed down to radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery segment is also divided into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.
Based on end users, the market has been classified as hospitals, clinics, diagnostic centers, speciality clinics, research institutes, and others.
Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. The Western Europe segment has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East and Africa have been divided into the Middle East and Africa.
North America bosting of its key players operating in the manufacturing of medical devices are adopting the latest medical technologies is expected to augment the pulmonary atresia diagnostics and treatment market in the upcoming year in the region.
Followed by North America, the European market is likely to hold the second largest market share. Increase in research and development activities to develop more effective treatment for pulmonary atresia owing to the strong medical manufacturing base of the region are the factors impelling the market growth.
The global pulmonary atresia diagnostics and treatment market in the Asia Pacific region is expected to proliferate at a steady rate in the forecast year 2017-2023. The Middle East & Africa is predicted to hold the smallest market share due to lack of required medical infrastructure.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar